

Prevalence and Determinants of Mild Cognitive Impairment in elderly population at Primary Care Facilities.

ABSTRACT

Aims: To characterize the prevalence and profile of patients with mild cognitive impairment (MCI) among older adults attended at the first level of care and the possible factors associated with MCI.

Study design: Observational, descriptive, cross-sectional and analytical study.

Place and Duration of Study: Ambulatory Care Medical Unit. It was conducted with Mexican patients attending the outpatient consultation of the Gerontology Speciality at the Family Medicine Clinic "División del Norte", in Mexico City

Methodology: Data was collected through a protective design using the MOCA test and a structured survey on sociodemographic factors. A descriptive statistical analysis and univariate and multivariate logistic regression models were performed.

Results: The prevalence of MCI was 28%, and 18% for dementia. The elderly population with MCI are female, septuagenarian, with a basic level of education. The factors that increase the risk of MCI are: age (OR=1.072, 95% CI 1.034-1.111), hypertriglyceridemia (OR=13.709, 95%CI 1.267-148.294), peptic ulcer disease (OR=5.92, 95%CI 1.009-34.719), glaucoma (OR=4.048, 95%CI 1.051-15.596), chronic obstructive pulmonary disease (OR=5.616, 95%CI 1.024-30.802), and asthma (OR=12.323, 95%CI 1.128-134.578). The high educational level was associated as a protective factor (OR=0.336, 95%CI 0.189-0.596).

Conclusion: Prevention programs are required to avoid MCI, as well as interventions to improve patients' life quality, and the promotion of educational and engaging activities to support cognitive health in elderly people.

Keywords: elderly population; mild cognitive impairment; non transmissible chronic diseases; primary care; social security.

1. INTRODUCTION

Dementia is a growing public health, being a major cause of morbidity and dependency among older adults, according to the World Health Organization.[1] Currently, more than 55 million people worldwide have dementia, with over 60% living in low- and middle-income countries.[2] In Mexico, the prevalence of dementia due to Alzheimer's disease, vascular causes, and mixed origins are 7.8, 4.3, and 2.1%, respectively.[3] However, the most common cognitive condition in older adults is Mild Cognitive Impairment (MCI).

MCI is well established as a boundary between normal aging and very early dementia. Moreover, memory is not the only cognitive domain affected; one or more of the following six

cognitive domains can also be impacted, such as: learning and memory, language, complex attention, executive function, social cognition, and visuospatial function.[4] Therefore, MCI in older adults should be considered a preventable aspect of the natural aging process. It represents an initial stage in cognitive aging, where individuals can recognise that they have a problem with cognitive function.[5,6] This condition affects about 22.7% of older adults over 65 in Korea.[7] In this population, the prevalence of MCI decreased significantly with an increase in monthly income and with an increase in life quality, but it increased with an increase in depressive symptoms.[5]

In Chinese population, older age and being single are risk factors for MCI among older adults with multimorbidity.[8] Similar findings were observed in the Moroccan population, where a decrease in the Mini-Mental State Examination score was associated with increasing age (p -value = 0.004) in patients with type 2 diabetes.[9]

Previous studies have identified various risk factors for MCI.[5] Jia et al., reported that MCI had similar risk factors to those patients with dementia, such as old age, sex, family history, rural residence, low education, living alone, smoking, and chronic diseases.[5,10] Other researchers suggested additional risk factors, including subjective health, income level, a high-fat diet, and depression and anxiety.[5,11-13] According to Song et al., physical exercise is a protective factor that decreases the probability of MCI.[14]

Reviewing numerous studies, it makes possible to classify the associated factors for MCI into personal characteristics, health promotion activity characteristics, modifiable and non-modifiable factors,[4-5] and Social Determinants of Health (SDOH). The research focused on identifying the prevalence of probable MCI and their associated factors in older adults attended at the first level of care.

2. MATERIAL AND METHODS

2.1 Study Design and Setting.

An observational, descriptive, cross-sectional, and analytical study was designed. It was conducted with Mexican patients attending the outpatient consultation of the Gerontology Speciality (gerontological module) at the Family Medicine Clinic (FMC) "División del Norte", belonging to the State Employees' Social Security and Social Services Institute (ISSSTE by its acronyms in Spanish), in Mexico City, from August 1st to October 31st ,2023. Data collection was conducted using a protective design with two questionnaires: 1) a sociodemographic factors questionnaire, and 2) the Montreal Cognitive Assessment (MoCA). The study was carried out from December 2022 to March 2023.

2.2 Study population, Sampling Method and Sample Size Calculation.

The study included 382 elderly patients aged from 60 years old and above, from gerontological module, ISSSTE. Intentional sampling was utilised by selecting individuals who either self-reported cognitive complaints or whose caregiver or clinician reported cognitive issues. This method ensured the inclusion of patients with potential cognitive concerns relevant to the study's objectives. The sample size was calculated considering a known population of 7,195 elderly patients. A 95% confidence interval (95% CI; $Z=1.96$), a 5% precision error, and an estimated probability value of 47% ($p=0.47$; $q=0.53$) were used. The expected sample size was 363 individuals.

2.3 Data Collection and Instruments.

Data was collected using structured questionnaires, comprising a sociodemographic factors questionnaire and the MoCA version 8.1, which has been translated into Spanish. A data collection sheet was employed to gather detailed identification information (patient name, medical record number, date of birth, address, telephone number, type of entitlement),

sociodemographic characteristics (age, sex, educational level, marital status), anthropometric measurements (height, weight, and BMI), as well as a pathological history (chronic/degenerative diseases) and protective factors for cognitive decline (bilingualism, Mediterranean diet, statin use, physical activity, and recreational activities). The MoCA assessment was used to evaluate the cognitive function of participants. The MoCA assesses multiple cognitive domains including: attention, concentration, executive functions, memory, language, visuospatial skills, abstraction, calculation and orientation.[15] The cognitive function of patients was classified into three categories: Dementia (0 to 18 points), MCI (outcome) (19 to 22 points), and patients with normal cognitive function (23 to 30 points), according to results of Pedraza et al, in elderly patients aged 60 and over (sensitivity 72.9%, specificity 61.8%).[16] This assessment was administered individually by a healthcare professional, who had received formal training on the official MoCA website (<https://mocacognition.com/>). Each MoCA assessment was conducted in a single session within a controlled, quiet, and private environment to minimise distractions and optimise participant comfort. Each session lasted approximately 10 minutes. This setting ensured that participants could perform to the best of their abilities during the cognitive evaluation.

2.4 Training and Standardisation.

The healthcare professional conducting the MoCA assessments underwent training to ensure standardisation and reliability in test administration and scoring. This training, accessed through the official MoCA website, provided the necessary competencies to accurately assess various cognitive domains, including attention, memory, language, visuospatial skills, executive functions, and orientation.

2.5 Selection criteria.

Participants were selected based on the following inclusion criteria: elderly individuals of both sexes, aged 60 years old or over, attending the outpatient consultation of the gerontological module. They had to have at least five years of education, no visual impairment or total blindness, no language disability, and complete information on the study variables. Additionally, participants needed to voluntarily agree to participate in the study and sign the informed consent. Exclusion criteria were as follows: elderly individuals who did not sign the informed consent, individuals who were illiterate or had less than five years of education, those with visual impairment or total blindness, those with a language disability, and those with incomplete information on the study variables. Elimination criteria included patients diagnosed with mental disorders such as depression, anxiety, or schizophrenia.

2.6 Data Recording and Statistical Analysis.

Immediately following the MoCA assessment, results were recorded and scored. These scores were then systematically compiled and analysed to determine the cognitive status of participants. The sociodemographic data, anthropometric measurements, pathological history, and protective factors were also analysed to identify correlations and potential risk factors associated with cognitive decline. This methodical approach to data collection and cognitive assessment provided a robust framework for understanding the prevalence and determinants of cognitive impairment in the study population. Categorical variables were described using absolute and relative frequencies (percentages) with their 95% CI. Quantitative variables were described using mean, standard deviation (SD), median (Md), and interquartile range (IQR). Categorical variables were compared using the chi-square test (χ^2) with Yates' correction and Fisher's exact test as appropriate. Quantitative variables were compared using Student's t-test for independent samples and the median test for independent samples. Associations between possible sociodemographic factors were analysed using univariate and multivariate logistic regression models. The data was analysed as numerical and dichotomous variables. A p-value < 0.05 (two-tailed test) was considered significant.

2.7 Ethical Considerations.

The study was conducted in accordance with the Good Clinical Practice Guidelines of our laws and the Declaration of Helsinki for human experiments. The protocol was approved by two committees: The Research Committee and the Ethics Committee in Research of the FMC "División del Norte", ISSSTE. The Data was treated confidentially.

3. RESULTS AND DISCUSSION

3.1 General characteristics of study population.

The average age, weight, height, and body mass index are shown in Table 1. The median age was 72 years old (IQR=66-78 years). The youngest participant was 60 years old and the oldest was 93 years old (range=33 years). Nearly 54% of the elderly individuals had normal cognitive function. The prevalence of MCI was 28% and that of dementia was 18.1% (Table 1). The majority of the participants were women, septuagenarians, and sexagenarians. The top 10 comorbidities observed were: hypertension, type 2 diabetes, overweight (BMI between 27 and 31.99), smoking, history of obesity, obesity (BMI 32 and above), chronic venous disease, hypothyroidism, hypercholesterolemia, and alcoholism (Table 1). All observed comorbidities are listed in Table 1. The main protective factor observed in our population, according to the literature, was physical activity, followed by bilingualism, recreational activities, and statin use (Table 1).

Table 1. General characteristics of the study population.

Variables	Frequency, percentage (95% CI)
MoCA, mean (SD)	22.47 (4.63)
No Cognitive Impairment (23 to 30)	206, 53.9 (48.4-58.9)
Mild Cognitive Impairment (19-22)	107, 28 (23.6-32.5)
Dementia (0-18)	69, 18.1 (14.1-22.3)
Male	129, 33.8 (29.1-38.5)
Female	253, 66.2 (61.5-70.9)
Age, mean (SD)	72.25 (7.78)
Sexagenarian	153, 40.1 (35.6-45)
Septuagenarian	158, 41.4 (36.4-46.3)
Octogenarian	64, 16.8 (13.1-20.7)
Nonagenarian	7, 1.8 (0.5-3.4)
Weight (Kg), mean (SD)	68.31 (12.22)
Height (Metres), mean (SD)	1.58 (0.09)
BMI, mean (SD)	27.26 (4.06)
Underweight <22	22, 5.8 (3.4-8.1)
Normal Weight (22 to 26.99)	176, 46.1 (41.1-51.3)
Overweight (27 to 31.99)	145, 38 (33.2-43.2)
Obesity (32 and above)	39, 10.2 (7.3-13.1)
History of Obesity	76, 19.9 (15.4-23.8)
Type 2 Diabetes	172, 45 (39.8-50)
Prediabetes	12, 3.1 (1.6-5)
Hypercholesterolemia	24, 6.3 (3.9-8.6)
Hypertriglyceridemia	6, 1.6 (0.5-3.1)
Hypertension	234, 61.3 (56.3-66)
Smoking	85, 22.3 (18.3-26.4)
Alcoholism	24, 6.3 (3.9-8.9)
Cardiovascular Risk	1, 0.3 (0-0.8)
Ischaemic Heart Disease	17, 4.5 (2.6-6.5)

Hypertensive Heart Disease	3, 0.8 (0-1.8)
Mixed Heart Disease	2, 0.5 (0-1.3)
Ischaemic Stroke	7, 1.8 (0.5-3.4)
Haemorrhagic Stroke	2, 0.5 (0-1.3)
Sinus Bradycardia	1, 0.3 (0-1)
Atrioventricular Block with Pacemaker	1, 0.3 (0-0.8)
Aortic Valve Carrier	1, 0.3 (0-0.8)
Chronic Heart Failure	1, 0.3 (0-0.8)
Atrial Fibrillation	2, 0.5 (0-1.3)
Arrhythmia	1, 0.3 (0-0.8)
Chronic Venous Disease	28, 7.3 (4.7-9.9)
Diabetic Neuropathy	3, 0.8 (0-1.8)
Gait Disorder	1, 0.3 (0-0.8)
Essential Tremor	1, 0.3 (0-0.8)
Urinary Incontinence	5, 1.3 (0.3-2.6)
Parkinson's Disease	2, 0.5 (0-1.3)
Epilepsy	1, 0.3 (0-0.8)
Multiple Sclerosis	1, 0.3 (0-0.8)
Gonarthrosis	19, 5 (2.9-7.3)
Osteoporosis	17, 4.5 (2.4-6.5)
Low Back Pain	11, 2.9 (1.3-4.7)
Disc Disease	1, 0.3 (0-0.8)
Discartrosis	1, 0.3 (0-0.8)
Coxarthrosis	1, 0.3 (0-0.8)
Chronic Kidney Disease	11, 2.9 (1.3-4.7)
Benign Prostatic Hyperplasia	18, 4.7 (2.6-6.8)
Hyperuricemia – Gout	3, 0.8 (0-1.8)
Overactive Bladder	1, 0.3 (0-0.8)
Kidney Stones	1, 0.3 (0-0.8)
Rheumatoid Arthritis	8, 2.1 (0.8-3.7)
Osteoarthritis	13, 3.4 (1.8-5.5)
Hypothyroidism	28, 7.3 (4.7-9.9)
Hyperthyroidism	1, 0.3 (0-0.8)
Atopic Dermatitis	12, 3.1 (1.3-5)
Psoriasis	2, 0.5 (0-1.3)
Sleep Disorder	3, 0.8 (0-1.6)
Depression	11, 2.9 (1.3-4.7)
Anxiety Disorder	12, 3.1 (1.6-5)
Schizophrenia	1, 0.3 (0-0.8)
Irritable Bowel Syndrome	11, 2.9 (1.3-4.7)
Gastroesophageal Reflux Disease	1, 0.3 (0-0.8)
Peptic Ulcer Disease	10, 2.6 (1.3-4.5)
Diverticular Disease	3, 0.8 (0-1.8)
Upper Digestive Tract Bleeding	1, 0.3 (0-0.8)
Glaucoma	13, 3.4 (1.6-5.2)
Hearing Loss	21, 5.5 (3.1-7.9)
Chronic Obstructive Pulmonary Disease	9, 2.4 (1-4.2)
Asthma	5, 1.3 (0.3-2.6)
COVID-19 Disease	127, 33.3 (28.5-38.2)
Thyroid Cancer	1, 0.3 (0-0.8)
Colon Cancer	1, 0.3 (0-0.8)

Ovarian Cancer	1, 0.3 (0-0.8)
Prostate Cancer	2, 0.5 (0-1.3)
Fatty Liver	2, 0.5 (0-1.3)
Liver Failure	1, 0.3 (0-0.8)
Discoid Lupus	1, 0.3 (0-0.8)
Non-Hodgkin Lymphoma	1, 0.3 (0-0.8)
Bilingualism	20, 5.2 (3.1-7.6)
Mediterranean Diet	0, 0.0 (0-0)
Statin Use	2, 0.5 (0-1.3)
Physical Activity	38, 9.9 (7.1-13.1)
Recreational Activities	11, 2.9 (1.3-4.7)

Source: Own elaboration with the results from the database.

3.2 Population with Mild Cognitive Impairment.

The widely held elderly population with MCI are female, septuagenarian, with a basic level of education, and a normal weight. The main 15 comorbidities observed in this population group include hypertension, type 2 diabetes, smoking, history of obesity, gonarthrosis, hypercholesterolemia, glaucoma, chronic venous disease, hearing loss, alcoholism consumption, prediabetes, osteoarthritis, peptic ulcer disease, chronic obstructive pulmonary disease, and hypothyroidism (table 2). When comparing the prevalence of non-transmissible chronic diseases between elderly with normal cognitive function and those with MCI, we observed a greater prevalence of hypertriglyceridemia, peptic acid disease, glaucoma, and chronic obstructive pulmonary disease in those patients with MCI (table 2).

Table 2. Comparison between the normal cognitive function versus mild cognitive impairment population.

Variables	NCF (n=206)	MCI (n=107)
Male	70, 34 (27.7-40.3)	35, 32.7 (24.3-42.1)
Female	136, 66 (59.7-72.3)	72, 67.3 (57.9-75.7)
Sexagenarian	107, 51.9 (44.7-59.2)	35, 32.7 (23.4-42.1)
Septuagenarian	78, 37.9 (31.6-44.7)	49, 45.8 (36.4-55.1)
Octogenarian	21, 10.2 (6.3-15)	19, 17.8 (11.2-25.2)
Nonagenarian	0, 0.0 (0.0-0.0)	4, 3.7 (0.9-7.5)
Education*		
BE	114, 55.3 (49-62.6)	82, 76.6 (68.2-84.1)
HPE	92, 44.7 (37.4-51)	25, 23.4 (15.9-31.8)
Underweight	11, 5.3 (2.4-8.7)	9, 8.4 (3.7-14)
Normal Weight	96, 46.6 (40.3-52.9)	49, 45.8 (35.5-55.1)
Overweight	74, 35.9 (29.6-43.2)	39, 36.4 (27.1-45.8)
Obesity	25, 12.1 (7.8-16.5)	10, 9.3 (4.7-15)
Type 2 Diabetes	89, 43.2 (36.9-49)	51, 47.7 (38.3-57)
Prediabetes	6, 2.9 (1-5.3)	6, 5.6 (1.9-10.3)
Hypertension	124, 60.2 (53.4-67)	70, 65.4 (56.1-74.8)
Chronic Kidney Disease	7, 3.4 (1-5.8)	1, 0.9 (0-3.7)
Gonarthrosis	5, 2.4 (0.5-4.9)	8, 7.5 (2.8-13.1)
Cardiovascular Risk	1, 0.5 (0-1.5)	0, 0 (0-0)
Ischaemic Stroke	3, 1.5 (0-3.4)	2, 1.9 (0-4.7)
Haemorrhagic Stroke	2, 1 (0-2.4)	0, 0 (0-0)
Diabetic Neuropathy	2, 1 (0-2.4)	0, 0 (0-0)
Depression	7, 3.4 (1.5-6.3)	2, 1.9 (0-4.7)
Osteoporosis	13, 6.3 (3.4-10.2)	2, 1.9 (0-4.7)

Low Back Pain	7, 3.4 (1.5-6.3)	3, 2.8 (0-5.6)
Diabetic nephropathy	0, 0 (0-0)	1, 0.9 (0-2.8)
Gait Disorder	1, 0.5 (0-1.5)	0, 0 (0-0)
Hypertriglyceridemia**	1, 0.5 (0-1.5)	4, 3.7 (0.9-7.5)
Retinopathy	0, 0 (0-0)	0, 0 (0-0)
Ischaemic Heart Disease	10, 4.9 (2.4-8.3)	2, 1.9 (0-4.7)
Hypertensive Heart Disease	1, 0.5 (0-1.5)	1, 0.9 (0-2.8)
Mixed Heart Disease	0, 0 (0-0)	0, 0 (0-0)
BPH	13, 6.3 (2.9-10.2)	4, 3.7 (0.9-7.5)
History of Obesity	47, 22.8 (17.5-28.2)	20, 18.7 (11.2-26.2)
Radiculopathy	0, 0 (0-0)	0, 0 (0-0)
Hypercholesterolemia	14, 6.8 (3.4-10.2)	8, 7.5 (2.8-13.1)
Smoking	49, 23.8 (18-29.6)	21, 19.6 (12.1-27.1)
Rheumatoid Arthritis	2, 1 (0-2.4)	2, 1.9 (0-4.7)
Osteoarthritis	7, 3.4 (1-6.3)	6, 5.6 (1.9-10.3)
Hypothyroidism	19, 9.2 (5.8-13.6)	5, 4.7 (0.9-8.4)
Hyperthyroidism	1, 0.5 (0-1.5)	0, 0 (0-0)
Atopic Dermatitis	9, 4.4 (1.9-7.3)	1, 0.9 (0-2.8)
Sinus Bradycardia	0, 0 (0-0)	0, 0 (0-0)
Irritable Bowel Syndrome	6, 2.9 (1-5.8)	3, 2.8 (0-6.5)
Sleep Disorder	2, 1 (0-2.4)	0, 0 (0-0)
Anxiety Disorder	6, 2.9 (1-5.3)	5, 4.7 (0.9-8.4)
GRD	0, 0 (0-0)	0, 0 (0-0)
Peptic Ulcer Disease**	2, 1 (0-2.4)	6, 5.6 (1.9-11.2)
Diverticular Disease	1, 0.5 (0-1.5)	2, 1.9 (0-4.7)
Chronic Venous Disease	16, 7.8 (4.4-11.7)	7, 6.5 (1.9-11.2)
Glaucoma**	4, 1.9 (0.5-3.9)	8, 7.5 (2.8-12.1)
Hearing Loss	8, 3.9 (1.5-6.8)	7, 6.5 (2.8-11.2)
COPD**	2, 1 (0-2.4)	6, 5.6 (1.9-10.3)
Psoriasis	0, 0 (0-0)	1, 0.9 (0-2.8)
Schizophrenia	0, 0 (0-0)	1, 0.9 (0-2.8)
Urinary Incontinence**	1, 0.5 (0-1.5)	4, 3.7 (0.9-7.5)
Parkinson's Disease	0, 0 (0-0)	1, 0.9 (0-2.8)
Epilepsy	0, 0 (0-0)	1, 0.9 (0-2.8)
Thyroid Cancer	1, 0.5 (0-1.5)	0, 0 (0-0)
Asthma**	1, 0.5 (0-1.5)	4, 3.7 (0.9-7.5)
Discartrosis	0, 0 (0-0)	1, 0.9 (0-3.7)
Arrhythmia	0, 0 (0-0)	1, 0.9 (0-2.8)
Coxarthrosis	0, 0 (0-0)	1, 0.9 (0-2.8)
Multiple Sclerosis	0, 0 (0-0)	1, 0.9 (0-2.8)
Colon Cancer	1, 0.5 (0-1.9)	0, 0 (0-0)
Ovarian Cancer	1, 0.5 (0-1.5)	0, 0 (0-0)
Prostate Cancer	0, 0 (0-0)	2, 1.9 (0-4.7)
ABP	0, 0 (0-0)	1, 0.9 (0-2.8)
Aortic Valve Carrier	0, 0 (0-0)	0, 0 (0-0)
Hyperuricemia – Gout	3, 1.5 (0-3.4)	0, 0 (0-0)
Overactive Bladder	1, 0.5 (0-1.5)	0, 0 (0-0)
Essential Tremor	1, 0.5 (0-1.5)	0, 0 (0-0)
Fatty Liver	2, 1 (0-2.4)	0, 0 (0-0)
UDTB	1, 0.5 (0-1.5)	0, 0 (0-0)
Metastatic breast cancer	0, 0 (0-0)	0, 0 (0-0)

Disc Disease	0, 0 (0-0)	1, 0.9 (0-2.8)
Liver Failure	0, 0 (0-0)	1, 0.9 (0-2.8)
Discoid Lupus	1, 0.5 (0-1.5)	0, 0 (0-0)
Non-Hodgkin Lymphoma	1, 0.5 (0-1.5)	0, 0 (0-0)
Kidney Stones	0, 0 (0-0)	0, 0 (0-0)
Craniocerebral Trauma	0, 0 (0-0)	0, 0 (0-0)
Obstructive sleep apnea	0, 0 (0-0)	0, 0 (0-0)
Chronic Heart Failure	0, 0 (0-0)	1, 0.9 (0-2.8)
Atrial Fibrillation	0, 0 (0-0)	1, 0.9 (0-2.8)
Alcoholism	10, 4.9 (2.4-7.8)	7, 6.5 (2.8-12.1)
Social isolation	0, 0 (0-0)	0, 0 (0-0)
High IQ	0, 0 (0-0)	0, 0 (0-0)
Bilingualism	16, 7.8 (4.4-12.1)	4, 3.7 (0.9-7.5)
Mediterranean Diet	0, 0 (0-0)	0, 0 (0-0)
Statin Use	1, 0.5 (0-1.5)	1, 0.9 (0-2.8)
Physical Activity	23, 11.2 (6.8-15.5)	8, 7.5 (2.8-13.1)
Recreational Activities	6, 2.9 (1-5.3)	3, 2.8 (0-6.5)

Source: Own elaboration with the results from the database. NCF: normal cognitive function. MCI: mild cognitive impairment. BE: Basic education. HPE: Higher and postgraduate education. UDTB: Upper Digestive Tract Bleeding. ABP: Atrioventricular Block with Pacemaker. COPD: Chronic Obstructive Pulmonary Disease. GRD: Gastroesophageal Reflux Disease. BPH: Benign Prostatic Hyperplasia. Underweight (<22 kg/m²). Normal Weight (22 to 26.99 kg/m²). Overweight (27 to 31.99 kg/m²). Obesity (32 kg/m² and above). * P value ≤0.001. ** P value <0.05.

3.3 Factors associated with Mild Cognitive Impairment.

Table 3 shows the multivariate model with the best predictive accuracy. Data from the univariate models indicate that the risk of MCI, in older adults, is higher in those with peptic acid disease (6 times higher compared to their counterparts without the disease), at least 4 times higher in patients with glaucoma, and 6 times higher in patients with chronic obstructive pulmonary disease. The data also indicate that having a higher educational level is a protective factor for reducing the likelihood of MCI. In the multivariate analysis model, we observe that the independent risk variables are: hypertriglyceridemia, peptic acid disease, glaucoma, chronic obstructive pulmonary disease, and asthma. Similarly, the only independent protective factor was high education. For both the multivariate and univariate models, age is a risk factor. The models indicate that the probability of MCI increases with age.

Table 3. Factors associated with mild cognitive impairment.

Variable	NCF (n= 206) n (%)	MCI (n=107) n (%)	RM crude (95% IC)	P ^a	RM adjusted (95% IC)	P ^b
Age			1.070 (1.035-1.106)	<0.00 1	1.072 (1.034-1.111)	<0.00 1
Education (1)						
BSE (0)	114(55.3)	82(76.6)	1 (reference)		1 (reference)	
HPE (1)	92(44.7)	25(23.4)	0.378 (0.223-0.639)	<0.00 1	0.336 (0.189-0.596)	<0.00 1
HTG (1)						
No (0)	205(99.5)	103(96.3)	1 (reference)		1 (reference)	

Yes (1)	1(0.5)	4(3.7)	7.961 (0.879-72.142)	0.065	13.709 (1.267-148.294)	0.031
PUD (1)						
No (0)	204(99)	101(94.4)	1 (reference)		1 (reference)	
Yes (1)	2(0.97)	6(5.6)	6.059 (1.202-30.557)	0.029	5.92 (1.009-34.719)	0.049
Glaucoma (1)						
No (0)	202(98.1)	99(92.5)	1 (reference)		1 (reference)	
Yes (1)	4(1.9)	8(7.5)	4.081 (1.200-13.879)	0.024	4.048 (1.051-15.596)	0.042
COPD (1)						
No (0)	204(99)	101(94.4)	1 (reference)		1 (reference)	
Yes (1)	2(0.97)	6(5.6)	6.059 (1.202-30.557)	0.029	5.616 (1.024-30.802)	0.047
Asthma (1)						
No (0)	205(99.5)	103(96.3)	1 (reference)		1 (reference)	
Yes (1)	1(0.48)	4(3.7)	7.961 (0.879-72.142)	0.065	12.323 (1.128-134.578)	0.039

Source: Own elaboration with the results from the database. NCI: normal cognitive impairment. MCI: mild cognitive impairment. COPD: Chronic Obstructive Pulmonary Disease. BSE: Basic and Secondary Education. HPE: Higher and postgraduate education. PUD: Peptic ulcer disease. HTG: Hypertriglyceridemia. a. p-value determined by univariate regression models. b. p-value determined by multivariate regression model. Variables included in the multivariate regression model: Education (Basic and Secondary Education=0, Higher and Postgraduate Education=1), Hypertriglyceridemia (No=0; Yes=1), Peptic ulcer disease (No=0; Yes=1), Glaucoma (No=0; Yes=1), Chronic Obstructive Pulmonary Disease (No=0; Yes=1), Asthma (No=0; Yes=1). Beta values: age: 0.069; education (1): -1.092; hypertriglyceridemia (1): 2.618; PUD (1): 1.778; glaucoma (1): 1.398; COPD (1): 1.726; asthma (1): 2.512; Constant: -5.483.

It's well established that the population of Latin America and the Caribbean is aging rapidly, presenting the highest prevalence rates of dementia in the world.[17] Moreover, substantial evidence indicates that 10–15% of individuals with MCI aged over 65, develop dementia annually.[17-19] The study population had a median age of 72 years old, with a range spanning from 60 to 93 years old. Interestingly, 54% of the participants maintained normal cognitive function, while 28% exhibited MCI, and 18.1% had dementia. This distribution highlights the substantial proportion of elderly individuals at risk for cognitive decline. The prevalence of dementia in LAC countries is high and still increasing compared with estimations in Europe and the United States.[17, 20-21] For this reason, it is essential to comprehend transitional states to dementia, such as MCI and their underlying associated factors. Furthermore, knowledge about the prevalence of MCI defines the target population that would benefit most from public health interventions. Our results provide evidence that public health programs are needed to improve the cognitive health of elderly people. Public health interventions targeting people with MCI would further reduce the risk of dementia and the associated challenges for public health systems, especially in low- and middle-income countries.[17] From a public health perspective, to be timely and cost-efficient, interventions

aiming at reducing the risk of dementia should focus on at-risk individuals.[17] While other studies have focused on interventions to eliminate or reduce dementia risk factors, defining the at-risk population with MCI is important to provide better projections of dementia prevalence and identify the population strata with the highest potential to benefit from interventions.[17,22] In our study, the major comorbidities observed include hypertension, type 2 diabetes, overweight, smoking, history of obesity, obesity, chronic venous disease, hypothyroidism, hypercholesterolemia, and alcoholism. These conditions are prevalent among the elderly and influence overall health and cognitive function. Among those with MCI, the majority were women, people in their seventies and with a baseline level of education. Sex remains controversial. Some studies found no sex differences (similar to our study), while others indicated a higher prevalence of MCI in men (different to the prevalence observed in our study population).[23-26] The presence of comorbidities such as hypertension, type 2 diabetes, smoking, history of obesity, gonarthrosis, hypercholesterolemia, glaucoma, chronic venous disease, hearing loss, alcoholism, prediabetes, osteoarthritis, peptic ulcer disease, chronic obstructive pulmonary disease, and hypothyroidism was notably high in people with MCI. This suggests a complex interaction between multiple health conditions and cognitive decline.

Regarding the risk factors associated with MCI, previous studies have identified various factors: old age, sex, family history, rural residence, low education, living alone, being single, smoking, income level, a high-fat diet, and chronic diseases.[5, 8-13, 26-30] In our study, univariate analysis highlights that the risk of MCI is significantly higher in oldest adults, individuals with peptic acid disease, glaucoma, and chronic obstructive pulmonary disease. Specifically, those with peptic acid disease have a six-fold increased risk, those with glaucoma have at least a four-fold increased risk, and those with chronic obstructive pulmonary disease also have a six-fold increased risk. These findings underscore the importance of managing these conditions to potentially mitigate the risk of cognitive decline. Both univariate and multivariate models identified age as a significant risk factor for MCI. As age increases, so does the likelihood of cognitive decline. This is consistent with the understanding that aging is a primary risk factor for cognitive decline, highlighting the need for targeted interventions in older populations.

According to the literature, physical activity, bilingualism, recreational activities, and statin use are significant protective factors against cognitive decline and provide cognitive health benefits. However, in our study population educational level was the only protective factor. Educational level emerged as a strong protective factor against MCI. Higher education levels were associated with a lower likelihood of developing MCI, suggesting that cognitive reserve built through education may provide resilience against cognitive decline. This aligns with the broader body of research emphasizing the protective effects of lifelong learning and mental engagement.

4. CONCLUSION

this study provides evidence and underscores the multifaceted nature of MCI, with various non transmissible chronic diseases contributing to increased risk, while higher education serves as a protective factor. The findings argue for comprehensive management of comorbidities and the promotion of educational and engaging activities to support cognitive health in the elderly. We found a higher prevalence of MCI compared to populations from Peru and the United States of America. Future research should continue to explore these relationships and develop tailored interventions to address the specific needs of individuals at risk for mild cognitive impairment.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Authors hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of manuscripts.

CONSENT

A medical professional informed all participants about the study's objective, its benefits, and potential adverse events. After providing a clear explanation, the signatures of those who voluntarily decided to participate in the study were collected, ensuring that participants had sufficient time to read and sign the corresponding informed consent form.

ETHICAL APPROVAL

The study was conducted in accordance with the Good Clinical Practice Guidelines of our laws and the Declaration of Helsinki for human experiments. The protocol was approved by two committees: The Research Committee and the Ethics Committee in Research of the FMC "División del Norte", ISSSTE. The Data was treated confidentially.

The study was conducted in accordance with the Good Clinical Practice Guidelines of our laws and the Declaration of Helsinki for human experiments. The protocol was approved by two committees: The Research Committee and the Ethics Committee in Research of the FMC "División del Norte", ISSSTE. The Data was treated confidentially.

REFERENCES

1. Mohan D, Iype T, Varghese S, Usha A, Mohan M. A cross-sectional study to assess prevalence and factors associated with mild cognitive impairment among older adults in an urban area of Kerala, South India. *BMJ Open* 2019;9:e025473. doi:10.1136/bmjopen-2018-025473
2. Organización Mundial de la Salud. Demencia. Datos y cifras. 15 de marzo de 2023. Available from: <https://www.who.int/es/news-room/fact-sheets/detail/dementia>
3. Juarez-Cedillo T, Gonzelez-Figueroa E, Gutierrez-Gutierrez L, Aguilar-Navarro SG, Garcia-Cruz JC, Escobedo de la Peña J, et al. Prevalence of Dementia and Main Subtypes in Mexico: The Study on Aging and Dementia in Mexico (SADEM). *J Alzheimers Dis*. 2022;89(3):931-941. doi: 10.3233/JAD-220012.
4. Anand S, Schoo C. Mild Cognitive Impairment. [Updated 2024 Jan 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK599514/>
5. Hwang EJ. Analysis of Factors Associated with Subjective Mild Cognitive Impairment (MCI) among Older Adults Resident in the Community. *Int J Environ Res Public Health*. 2022;19(16):10387. doi: 10.3390/ijerph191610387.
6. Petersen RC. Mild Cognitive Impairment. *Continuum (Minneapolis)*. 2016 Apr;22(2 Dementia):404-18. doi: 10.1212/CON.0000000000000313.
7. Korea Central Dementia Center. DementiaPrevalence. 2019. Availableonline: https://www.nid.or.kr/info/today_list.aspx (accessed on 9 December 2021).
8. Xu Z, Zhang D, Sit RWS, Wong C, Tiu JYS, Chan DCC, et al. Incidence of and Risk factors for Mild Cognitive Impairment in Chinese Older Adults with Multimorbidity in Hong Kong. *Sci Rep*. 2020;10(1):4137. doi: 10.1038/s41598-020-60901-x.

9. Rhmari-Tlemçani FZ, Elamari S, Motaib I, Laidi S, Alidrisi N, Ahid S, et al. Factors associated with mild cognitive impairment in patients with type 2 diabetes: A cohort study. *Cureus*. 2022;14(8):e28305. doi: 10.7759/cureus.28305.
10. Jia L, Dum Y, Chu L, Zhang Z, Li F, Lyu D, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: A cross-sectional study. *Lancet Public Health* 2020;5:e661–e671.
11. Byeon H. Mild cognitive impairment prediction model of elder in Korea using restricted boltzmann machine. *J. Converg. Inf. Technol.* 2019;9:248–253.
12. Wang Z, Hou J, Shi Y, Tan Q, Peng L, Deng Z, et al. Influence of lifestyles on mild cognitive impairment: A decision tree model study. *Clin. Interv. Aging*. 2020;28:2009–2017.
13. Alegret M, Rodriguez O, Espinosa A, Ortega G, Sanabria A, Valero S, et al. Concordance between subjective and objective memory impairment in volunteer subjects. *J. Alzheimer's Dis.* 2015;48:1109–1117.
14. Song D, Yu DSF, Li PWC, Lei Y. The effectiveness of physical exercise on cognitive and psychological outcomes in individuals with mild cognitive impairment: A systematic review and meta-analysis. *Int. J. Nurs. Stud.* 2018;79:155–164.
15. Julayanont P, Phillips N, Chertkow H, Nasreddine ZS. The Montreal Cognitive Assessment (MoCA): Concept and Clinical Review. To appear in A.J. Larner (Ed.), *Cognitive Screening Instruments: A Practical Approach*. Springer-Verlag, pp. 111-152.
16. Pedraza OL, Salazar AM, Sierra-Fabio A, Soler D, Castro J, Castillo P et al. Reliability, criterion and discriminant validity of the Montreal Cognitive Assessment Test (MoCA) in a group of adults from Bogotá. *Acta Med Colomb.* 2016;41(4):221-228.
17. Ribeiro FS, Teixeira-Santos AC, Leist AK. The prevalence of mild cognitive impairment in Latin America and the Caribbean: a systematic review and meta-analysis. *Aging Ment Health.* 2022;26(9):1710-1720. doi: 10.1080/13607863.2021.2003297.
18. Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, Gloss D, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology.* 2018;90(3):126-135. doi: 10.1212/WNL.0000000000004826.
19. Roberts R, Knopman DS. Classification and epidemiology of MCI. *Clin Geriatr Med.* 2013;29(4):753-72. doi: 10.1016/j.cger.2013.07.003.
20. Ibáñez A, Sedeño L, García AM, Deacon RMJ, Cogram P. Editorial: Human and Animal Models for Translational Research on Neurodegeneration: Challenges and Opportunities From South America. *Front Aging Neurosci.* 2018;10:95. doi: 10.3389/fnagi.2018.00095.
21. Parra MA, Baez S, Sedeño L, Gonzalez-Campo C, Santamaría-García H, Aprahamian I, et al. Dementia in Latin America: Paving the way toward a regional action plan. *Alzheimers Dement.* 2021;17(2):295-313. doi: 10.1002/alz.12202.
22. Mukadam N, Anderson R, Knapp M, Wittenberg R, Karagiannidou M, Costafreda SG, et al. Effective interventions for potentially modifiable late-onset dementia risk factors: Their costs and cost-effectiveness. *The Lancet Healthy Longevity.* 2020;1(1):E13–320.
23. Au B, Dale-McGrath S, Tierney MC. Sex differences in the prevalence and incidence of mild cognitive impairment: A meta-analysis. *Ageing Res Rev.* 2017;35:176-199. doi: 10.1016/j.arr.2016.09.005.
24. Nie H, Xu Y, Liu B, Zhang Y, Lei T, Hui X, et al. The prevalence of mild cognitive impairment about elderly population in China: a meta-analysis. *Int J Geriatr Psychiatry.* 2011;26(6):558-63. doi: 10.1002/gps.2579.
25. Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. *Neurology.* 2004;63(1):115-21. doi: 10.1212/01.wnl.0000132523.27540.81.

26. Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS, et al. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. *Neurology*. 2010;75(10):889-97. doi: 10.1212/WNL.0b013e3181f11d85.
27. Pankratz VS, Roberts RO, Mielke MM, Knopman DS, Jack CR Jr, Geda YE, et al. Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging. *Neurology*. 2015;84(14):1433-42. doi: 10.1212/WNL.0000000000001437.
28. Sánchez SS, Abanto J, Sanchez-Boluarte A, Boluarte-Carbajal A, Sanchez-Coronel D, Custodio-Capuñay N, et al. Frequency and associated factors of amnesic mild cognitive impairment at four senior citizen clubs in Lima, Peru. *Dement Neuropsychol*. 2019;13(3):321-328. doi: 10.1590/1980-57642018dn13-030009.
29. Langa KM, Larson EB, Crimmins EM, Faul JD, Levine DA, Kabeto MU, et al. A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012. *JAMA Intern Med*. 2017;177(1):51-58. doi: 10.1001/jamainternmed.2016.6807.
30. Rentería MC, Mainly JJ, Vonk JM, Arango SM, Obregon AM, Samper-Ternent R, et al. Prevalence of mild cognitive impairment in Mexican older adults: Data from the Mexican Health and Aging Study (MHAS). 2020;medRxiv. 10.1101/2020.01.03.20016345